Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
(2001) In British Journal of Cancer 84(3). p.303-307- Abstract
- In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival... (More)
- In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1121414
- author
- Messori, A ; Vaiani, M ; Trippoli, S ; Rigacci, L ; Jerkeman, Mats LU and Longo, G
- organization
- publishing date
- 2001
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- chemotherapy, meta-analysis, survival, non-Hodgkin's lymphoma
- in
- British Journal of Cancer
- volume
- 84
- issue
- 3
- pages
- 303 - 307
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:11161392
- scopus:0035125066
- pmid:11161392
- ISSN
- 1532-1827
- DOI
- 10.1054/bjoc.2000.1566
- language
- English
- LU publication?
- yes
- id
- 2f02e4c4-a3a0-439a-b8e3-5380d30850d6 (old id 1121414)
- date added to LUP
- 2016-04-01 12:25:14
- date last changed
- 2022-01-27 03:27:32
@article{2f02e4c4-a3a0-439a-b8e3-5380d30850d6,
abstract = {{In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP.}},
author = {{Messori, A and Vaiani, M and Trippoli, S and Rigacci, L and Jerkeman, Mats and Longo, G}},
issn = {{1532-1827}},
keywords = {{chemotherapy; meta-analysis; survival; non-Hodgkin's lymphoma}},
language = {{eng}},
number = {{3}},
pages = {{303--307}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP}},
url = {{http://dx.doi.org/10.1054/bjoc.2000.1566}},
doi = {{10.1054/bjoc.2000.1566}},
volume = {{84}},
year = {{2001}},
}